Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

4(50%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

50%

Ph phase_2

25%

Ph not_applicable

13%

Ph phase_3

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

2(25.0%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

4(50.0%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(1)

Other(2)

Detailed Status

Recruiting3

unknown2

Active, not recruiting1

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (25.0%)

Phase 31 (12.5%)

Phase 44 (50.0%)

N/A1 (12.5%)

Trials by Status

active_not_recruiting113%

completed113%

recruiting338%

not_yet_recruiting113%

unknown225%

Recent Activity

4 active trials

Showing 5 of 8

recruitingphase_4

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228

recruitingphase_2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443

recruitingphase_3

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289

not_yet_recruitingnot_applicable

Prospective Clinical Study on the Clinical Efficacy and Prognostic Outcome of ICS/LABA Combined With Liqin Zhike Formula in the Treatment of Cough Variant Asthma

NCT07272278

active_not_recruitingphase_2

Oral Intake of Mg in Controlled Asthmatic Patients

NCT06721247

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06572228Phase 4

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Recruiting

NCT05851443Phase 2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Recruiting

NCT06750289Phase 3

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Recruiting

NCT07272278Not Applicable

Prospective Clinical Study on the Clinical Efficacy and Prognostic Outcome of ICS/LABA Combined With Liqin Zhike Formula in the Treatment of Cough Variant Asthma

Not Yet Recruiting

NCT06721247Phase 2

Oral Intake of Mg in Controlled Asthmatic Patients

Active Not Recruiting

NCT05596721Phase 4

Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma

Unknown

NCT02782312Phase 4

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

Completed

NCT01404013Phase 4

Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma